Peculiarities of acute gouty arthritis treatment in patients with concomitant pathology. Part 2: management of patients with cardiovascular, gastrointestinal, renal, liver diseases, pregnancy, also having anticoagulant therapy and patients in perioperative period

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatment of acute gouty arthritis involves the use of anti-inflammatory medicines (NSAIDs, glucocorticosteroids, colchicine), but their use in comorbid patients may be limited by contraindications or associated with risk of significant adverse effects. The second part of the article discusses the features of drug therapy for gouty attacks in patients with the most common diseases and clinical conditions.

Full Text

Restricted Access

About the authors

Vera V. Lyalina

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: vera_lyalina@mail.ru
ORCID iD: 0000-0002-4262-4060

PhD in Medical Sciences, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine, N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.

Elina A. Skripnichenko

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Department of Healthcare of Moscow

Email: elkaskrip@gmail.com
ORCID iD: 0000-0001-6321-8419

postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine, N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

Svetlana V. Borisovskaya

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Department of Healthcare of Moscow

Email: svabor@inbox.ru
ORCID iD: 0000-0002-9365-1472

PhD in Medical Sciences, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine, N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

Ruslan N. Obyedkov

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: rn.obedkov98@gmail.com
ORCID iD: 0000-0002-8689-6623

student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine, N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia.

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

Igor G. Nikitin

N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881

MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Porogov Russian National Research Medical University of the Ministry of Healthcare of Russia, director of Treatment and Rehabilitation Center of the Ministry of Healthcare of Russia

Russian Federation, 117997, Moscow, 1 Ostrovityanova Str.; Moscow

References

  1. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1-29. [Karateev A. E., Nasonov E. L., Ivashkin V. T. et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2018; 56(S1): 1-29 (In Russ.)]. https://dx.doi.org/10.14412/1995-4484-2018-1-29. EDN: PCPKRP.
  2. Simon L.S., Lanza F.L., Lipsky P.E. et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41(9):1591-602. https://dx.doi.org/10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J.
  3. Xu Z., Zhang R., Zhang D. et al. Peptic ulcer hemorrhage combined with acute gout: Analyses of treatment in 136 cases. Int J Clin Exp Med. 2015; 8(4): 6193-99.
  4. Haschek and Rousseaux’s handbook of toxicologic pathology. Ed. by Haschek W.M., Rousseaux C.G., Wallig M.A. Academic Press. 2013; 3054 pp. https://dx.doi.org/10.1016/C2010-1-67850-9. ISBN: 978-0-12-415759-0.
  5. Villa J., Cano A., Franco D. et al. Relevancia clínica de las interacciones medicamentosas entre antiinflamatorios no esteroideos y antihipertensivos. Atencion Primaria. 2014; 46(9): 464-74. [Villa J., Cano A., Franco D. et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Atencion Primaria = Primary Care. 2014; 46(9): 464-74 (In Spanish)]. https://dx.doi.org/10.1016/j.aprim.2013.11.010.
  6. Krum H., Swergold G., Curtis S.P. et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: Results from the MEDAL study. J Hypertens. 2009; 27(4): 886-93. https://dx.doi.org/10.1097/HJH.0b013e328325d831.
  7. Остроумова О.Д., Куликова М.И. Лекарственно-индуцированная артериальная гипертония. Системные гипертензии. 2019; 16(2): 32-41. [Ostroumova O.D., Kulikova M.I. Drug-induced arterial hypertension. Sistemnyye gipertenzii = Systemic Hypertension. 2019; 16(2): 32-41 (In Russ.)]. https://dx.doi.org/10.26442/2075082X.2019.2.180164. EDN: YBOMKF.
  8. Lovell A.R., Ernst M.E. Drug-induced hypertension: Focus on mechanisms and management. Curr Hypertens Rep. 2017; 19(5): 39. https://dx.doi.org/10.1007/s11906-017-0736-z.
  9. Cannon C.P., Curtis S.P., FitzGerald G.A. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006; 368(9549): 1771-81. https://dx.doi.org/10.1016/S0140-6736(06)69666-9.
  10. Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018; 12(2): 64-72. [Karateev A.E. Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: The importance of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018; 12(2): 64-72 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2018-2-64-72. EDN: XPPNNR.
  11. Stamp L.K., Chapman P.T. Gout and its comorbidities: Implications for therapy. Rheumatology (Oxford). 2013; 52(1): 34-44. https://dx.doi.org/10.1093/rheumatology/kes211.
  12. Spieker L.E., Ruschitzka F.T., Luscher T.F., Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail. 2002; 4(4): 403-10. https://dx.doi.org/10.1016/s1388-9842(02)00086-7.
  13. Ватутин Н.Т., Смирнова А.С., Целикова Е.О. Новые возможности в терапии сердечно-сосудистой патологии с использованием колхицина. Архив внутренней медицины. 2016; 6(3): 19-24. [Vatutin N.T., Smirnova A.S., Tselikova E.O. New possibilities in the treatment of cardiovascular pathology using colchicine. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine. 2016; 6(3): 19-24 (In Russ.)]. https://dx.doi.org/10.20514/2226-6704-2016-6-3-19-24. EDN: VZTUHR.
  14. Lucas G.N.C., Leitao A.C.C., Alencar R.L. et al. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol. 2019; 41(1): 124-30. https://dx.doi.org/10.1590/2175-8239-JBN-2018-0107.
  15. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci.. 2013; 16(5): 821-47. https://dx.doi.org/10.18433/j3vw2f.
  16. Harirforoosh S., Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6): 669-81. https://dx.doi.org/10.1517/14740330903311023.
  17. Ejaz P., Bhojani K., Joshi V.R. NSAIDs and kidney. J Assoc Physicians India. 2004; 52: 632-40.
  18. Andrassy K.M. Comments on «KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease». Kidney Int. 2013; 84(3): 622-23. https://dx.doi.org/10.1038/ki.2013.243.
  19. UpToDate. Gaffo A.L. Treatment of gout flares. 2022. URL: https://www.uptodate.com/contents/treatment-of-gout-flares (date of access - 01.03.2023).
  20. Bardin T., Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017; 15(1): 123. https://dx.doi.org/10.1186/s12916-017-0890-9.
  21. Фингер Д.Р. Гипоурикемические средства и колхицин. В кн.: Секреты ревматологии. Под ред. Стерлинга Дж. Уэста; пер. с англ. под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 683-690. [Finger D.R. Hypouricemic drugs and colchicine. In: Rheumatology secrets. Ed. by Sterling J. West; translation from English, ed. by O.M. Lesniak. Moscow: GEOTAR-Media. 2018; pp. 683-690 (In Russ.)]. ISBN: 978-5-9704-4508-2.
  22. Страчунский Л. С., Козлов С. Н. Глюкокортикоидные препараты. Методическое пособие. Смоленск: Смоленская государственная медицинская академия. 1997; 63[1] с. [Strachunsky L.S., Kozlov S.N. Glucocorticoids. Smolensk: Smolensk State Medical Academy. 1997; 63[1] pp. (In Russ.)]. ISBN: 5-86239-006-5
  23. Прилепская О.А., Дурова М.В., Лебедев И.А. Особенности медикаментозной терапии болевого синдрома у пациентов с терминальной почечной недостаточностью, получающих терапию хрониогемодиализом. Медицинский алфавит. 2017; 1(2): 9-12. [Prilepskaya O.A., Durova M.V., Lebedev I.A. Features of drug therapy of pain syndrome in patients with terminal renal failure receiving chroniohemodialysis therapy. Meditsinskiy alfavit = Medical Alphabet. 2017; 1(2): 9-12 (In Russ.)]. EDN: YSLUYH.
  24. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Colchicine. 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK548068/ (date of access - 01.03.2023).
  25. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Corticosteroids (Updated 2021 May 7). 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK548400/?rep (date of access - 01.03.2023).
  26. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. ID: 251. Доступ: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (дата обращения - 01.01.2023). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2018. ID: 251. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (date of access - 01.03.2023).
  27. Ушкалова Е.А., Зырянов С.К., Переверзев А.П. Клиническая фармакология нестероидных противовоспалительных средств. Учебное пособие. М.: МИА. 2018; 368 с. [Ushkalova E.A., Zyryanov S.K., Pereverzev A.P. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Tutorial. Moscow: MIA. 2018; 368 pp. (In Russ.)]. ISBN: 978-5-6040008-3-0.
  28. Reed G.W., Abdallah M.S., Shao M. et al. Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen. J Am Coll Cardiol. 2018; 71(16): 1741-51. https://dx.doi.org/10.1016/j.jacc.2018.02.036.
  29. Roberts W. N. Joint aspiration or injection in adults: Technique and indications. 2019. URL: https://www.uptodate.com/contents/joint-aspiration-or-injection-in-adults-technique-and-indications (date of access - 01.03.2023).
  30. Medsafe: New Zealand Medicines and Medical Devices Safety Authority. Dabigatran and gout or gout-like symptoms. 2018. URL: https://www.medsafe.govt.nz/safety/ews/2018/DabigatranAndGout.asp (date of access - 01.03.2023).
  31. Hak A.E., Curhan G.C., Grodstein .F, Choi H.K. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010; 69(7): 1305-9. https://dx.doi.org/10.1136/ard.2009.109884.
  32. Ушкалова Е., Ткачева О., Чухарева Н., Бевз А. Безопасность НПВС и ненаркотических анальгетиков в период беременности и лактации. Врач. 2010; (8): 10-12. [Ushkalova E., Tkacheva O., Chukhareva N., Bevz A. Safety of nonsteroidal anti-inflammatory drugs and nonnarcotic analgesics during pregnancy and lactation. Vrach = The Doctor. 2010; (8): 10-12 (In Russ.)]. EDN: MWJRRH.
  33. Koren G., Florescu A., Costei A.M. et al. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: A meta-analysis. Ann Pharmacother. 2006; 40(5): 824-29. https://dx.doi.org/10.1345/aph.1G428.
  34. Rigourd V., De Villepin B., Amirouche A. et al. Ibuprofen concentrations in human mature milk - First data about pharmacokinetics study in breast milk with AOR-10127 «Antalait» study. Ther Drug Monit. 2014; 36(5): 590-96. https://dx.doi.org/10.1097/FTD.0000000000000058.
  35. Indraratna P.L., Virk S., Gurram D., Day R.O. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology (Oxford). 2018; 57(2) :382-87. https://dx.doi.org/10.1093/rheumatology/kex353.
  36. Kelly W.N., Fox I.H., Palelleo T.D. Gout and related disorders of purine metabolism. In: Textbook of Rheumatology. WB Saunders. Philadelphia 1989; 1395 pp.
  37. Zhuo Y., Cai X., Hou Z. et al. Postoperative recurrent gout flares. J Clin Rheumatol. 2020; 26(5): 197-203. https://dx.doi.org/10.1097/RHU.0000000000001138.
  38. Jeong H., Jeon C.H. Clinical characteristics and risk factors for gout flare during the postsurgical period. Adv Rheumatol. 2019; 59(1): 31. https://dx.doi.org/10.1186/s42358-019-0075-7.
  39. Craig M.H., Poole G.V., Hauser C.J. Postsurgical gout. Am Surg. 1995; 61(1): 56-59.
  40. UpToDate. Muluk V., Cohn S.L., Whinney C. Perioperative medication management. 2022. URL: https://www.uptodate.com/contents/perioperative-medication-management (date of access - 01.03.2023).
  41. UpToDate. Axford J.S. Preoperative evaluation and perioperative management of patients with rheumatic diseases. 2020. URL: https://www.uptodate.com/contents/preoperative-evaluation-and-perioperative-management-of-patients-with-rheumatic-diseases#H11 (date of access - 01.03.2023).
  42. Springman S., Trapskin P.J., Hennes A. et al. Perioperative medication management. Adult/pediatric. Inpatient/ambulatory clinical practice guideline. University of Wisconsin Hospitals and Clinics Authority. 2020. URL: https://www.uwhealth.org/cckm/cpg/medica (date of access - 01.03.2023).
  43. FitzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020; 72(6): 744-60. https://dx.doi.org/10.1002/acr.24180.
  44. Preoperative Administration of Medicines for Elective Surgery. Canterbury district health board. 2020. URL: https://edu.cdhb.health.nz/Hospitals-Services/Health-Professionals/CDHB-Policies/Fluid-Medication- Manual/Documents/Preopera (date of access - 01.03.2023).
  45. Gow P. Treating gout in patients with comorbidities. Int J Clin Rheumtol. 2011; 6(6): 625-33. https://dx.doi.org/10.2217/ijr.11.63

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.

Download (323KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies